Max N. Wallace

MAX N. WALLACE, President and CEO, Cogent Neuroscience, Inc. has an
extensive history in biotechnology, having co-founded Sphinx
Pharmaceuticals (cellular signal transduction), Trimeris (viral fusion
inhibition) and SARCO (small molecule combinatorial chemistry). He
served as President and as a member of the Board of Directors of both
Trimeris and SARCO. Sphinx had a successful public offering and was
subsequently acquired by Eli Lilly & Co. Trimeris had successful initial
and secondary public offerings and, with partner Hoffman LaRoche, is
moving its first two anti-HIV drugs through clinical trials. SARCO was
acquired by PPD/Pharmaco. In addition, Mr. Wallace was a founding
management director of Duke Management Company, Duke University’s asset
management company. He received his BA from Duke University and his JD
from the University of Florida.